Perfood develops sinCephalea, a prescription digital therapeutic for migraine treatment that leverages personalized, blood sugar–stabilizing nutrition. The product translates scientific findings about individual glucose metabolism into digital health applications and pairs nutrition intervention with behavioral modulation features such as adherence management and patient education. Perfood tracks nutrition, activity, symptoms, medication and short-term glycemic responses for a limited two-week period, followed by a digital patient support program. The company plans to conduct clinical studies to advance its digital therapeutics and to expand the technology into other countries. Recent German legislation enabling prescription and reimbursement of digital health apps may support market access for sinCephalea. Perfood closed a €5M Series A to launch sinCephalea and support clinical and commercialization efforts.

Total raised

$6M

Funding rounds

1

Latest round

Series A

Latest activity

Dec 2020